If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now

A $1,000 investment in Halozyme Therapeutics made in September 2016 would be worth $10,866.33 as of September 1, 2026, representing a 986.63% gain. The biopharmaceutical company's success is driven by its ENHANZE drug delivery technology licensed to major pharma partners like Roche, Takeda, J&J, and AbbVie, generating royalties that comprise over 55% of revenues. While strong demand for partnered drugs and new collaboration deals support growth, biosimilar competition for blockbuster drugs and dependence on partner revenues present risks.